PharmaCorp Rx Inc.
PCRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 141.97% | -53.86% | -220.58% | 56.53% | 36.24% |
| Total Depreciation and Amortization | 72.41% | 94.03% | 79.24% | 190.29% | 731.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -283.19% | 903.64% | 143.05% | -73.53% | -893.33% |
| Change in Net Operating Assets | 1,349.77% | -1,028.37% | 141.07% | 215.90% | -92.66% |
| Cash from Operations | 506.30% | -2,225.91% | 36.35% | 184.75% | -24.26% |
| Capital Expenditure | -135.92% | -228.34% | -- | -- | -312.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 67.93% | -- | 105.06% | -387.04% | -1,356.83% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.82% | -- | -- | -- | -- |
| Cash from Investing | 87.99% | -296.26% | 83.91% | -288.33% | -4,330.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 27.34% | -110.06% | -214.68% | -49.88% | -158.17% |
| Issuance of Common Stock | -- | -- | -- | -58.58% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 583.57% | 645.89% | 42,799.18% | -59.80% | -100.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 118.31% | -5,075.41% | 251.89% | -192.33% | -116.89% |